Glioblastoma is the most aggressive form of brain cancer with an average life expectancy of just over a year following diagnosis. Unfortunately, there have been no new therapies since the introduction of the chemotherapy drug, Temozolomide, in 2005.
Dr Ryan Cross works in a multidisciplinary team of neuro-oncologists, neurosurgeons, consumers, and scientists in the Jenkins Lab at WEHI. The team aims to develop novel CARs for the treatment of brain cancers such as glioblastoma.
Dr Cross is an emerging leader in the brain cancer immunotherapy field and was awarded an early career fellowship from the Cure Brain Cancer Foundation in 2018. Since starting at WEHI he has led the development of a novel Chimeric Antigen Receptor pipeline from patient sample target identification using advanced mass spectrometry through to orthotopic brain tumour implantation.
